Nicotine transmucosal - Bionex Pharmaceuticals

Drug Profile

Nicotine transmucosal - Bionex Pharmaceuticals

Latest Information Update: 12 Dec 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Bionex Pharmaceuticals
  • Developer Bionex Pharmaceuticals; Rutgers
  • Class Alkaloids; Analgesics; Drug withdrawal therapies; Nicotine replacement therapy; Pyridines; Small molecules
  • Mechanism of Action Nicotinic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Smoking withdrawal

Most Recent Events

  • 12 Dec 2016 Chemical structure information added
  • 18 Nov 2016 Clinical trials in Smoking withdrawal in USA (Transmucosal) before November 2016
  • 31 Aug 2008 Bionex Pharmaceuticals receives phase I SBIR grant from National Institute on Drug Abuse for nicotine transmucosal development in Smoking withdrawal (3208592; Bionex Pharmaceuticals website)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top